Dean Bottino - Concepedia

Author

Dean Bottino

Takeda (United States)ORCID

Also Known As

D BOTTINO, D. Bottino, Dean Bottino, Dean C Bottino, Dean C. Bottino

Publications

971

Citations

H-Index

Concepts

All Affiliations

Takeda (United States)Millennium Engineering and Integration (United States)University of Utah Pfizer (United States)Princess Margaret Cancer Centre

About

Dean Bottino is an author at Takeda (United States) specializing in medicine, pharmacology, and engineering.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	114
2	Engineering	3	3	157
3	Business	1	1	13
4	Health Sciences	1	1	13
5	Social Sciences	1	1	12

Dean Bottino

Publications

398

Citations

H-Index

Page 1

	Year	Citations
A computational model of ameboid deformation and locomotion Dean Bottino, Lisa Fauci European Biophysics Journal Bipedal LocomotionEngineeringBiomechanicsBio-inspired RoboticsLegged Robot	1998	75
Modeling Viscoelastic Networks and Cell Deformation in the Context of the Immersed Boundary Method Dean Bottino Journal of Computational Physics Rheological Constitutive EquationCell DeformationViscoelastic NetworksEngineeringNonlinear Elasticity	1998	67
BCR–ABL Transcript Dynamics Support the Hypothesis That Leukemic Stem Cells Are Reduced during Imatinib Treatment Andrew M. Stein, Dean Bottino, Vijay Modur, Clinical Cancer Research	2011	48
A Phase I Monotherapy Study of RG7212, a First-in-Class Monoclonal Antibody Targeting TWEAK Signaling in Patients with Advanced Cancers Ulrik Lassen, Didier Meulendijks, L.L. Siu, Clinical Cancer Research	2014	45
A Systems Pharmacology Model for Drug Delivery to Solid Tumors by Antibody-Drug Conjugates: Implications for Bystander Effects Jackson Burton, Dean Bottino, Timothy W. Secomb The AAPS Journal Cell-based Drug DeliveryNanomedicineSystems Pharmacology ModelPolymer-drug ConjugateMedicine	2019	35
P1.13-44 Safety, PK, and Preliminary Antitumor Activity of the Oral EGFR/HER2 Exon 20 Inhibitor TAK-788 in NSCLC Joel W. Neal, Robert C. Doebele, Gregory J. Riely, Journal of Thoracic Oncology Inhibitor Tak-788MedicinePharmacologyP1.13-44 SafetyPharmacotherapy	2018	26
Dose Optimization for Anticancer Drug Combinations: Maximizing Therapeutic Index via Clinical Exposure-Toxicity/Preclinical Exposure-Efficacy Modeling Dean Bottino, Mayankbhai Patel, Ekta Kadakia, Clinical Cancer Research	2019	25
Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors Didier Meulendijks, Ulrik Lassen, Lillian L. Siu, Clinical Cancer Research	2015	24
Mathematical Modeling and Simulation to Investigate the CNS Transport Characteristics of Nanoemulsion-Based Drug Delivery Following Intranasal Administration Ekta Kadakia, Dean Bottino, Mansoor M. Amiji Pharmaceutical Research NanomedicineMathematical ModelingEngineeringMedicineTransport Phenomena	2019	15
Directional inconsistency between Response Evaluation Criteria in Solid Tumors (RECIST) time to progression and response speed and depth Kaitlyn E. Johnson, Axel Gomez, Jackson Burton, European Journal of Cancer Adaptive RadiotherapyMedical ImagingMedicineCancer RecurrenceDirectional Inconsistency	2019	13

Page 1